Bumetanide NDC 72205-056

NDC codes

FDA NDC Directory

Product NDC (as listed)72205-056Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72205-0056Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72205-056-91	72205005691	100 TABLET in 1 BOTTLE (72205-056-91)Marketed from Feb 10, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Bumetanide
Generic name (nonproprietary): bumetanide
Active ingredients: Bumetanide — .5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Novadoz Pharmaceuticals LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215362
Marketing start: Feb 5, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Increased Diuresis at Loop of Henle (Physiologic effect)
Identifiers: Product ID 72205-056_cddd33fb-25b0-49ca-ab32-7c79a9b3a384SPL ID cddd33fb-25b0-49ca-ab32-7c79a9b3a384SPL set ID cddd33fb-25b0-49ca-ab32-7c79a9b3a384RxCUI 197417, 197418, 197419UNII 0Y2S3XUQ5HUPC 0372205057913, 0372205056916, 0372205058057, 0372205058910, 0372205057050
Pharmacologic class: Loop Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472205005691 followed by a unit qualifier and the quantity

Package 72205-0056-91. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 10, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Bumetanide tablets, USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215362

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215362
Product	Strength	Form · route	Labeler	Product NDC
Bumetanide	Bumetanide 1 mg/1	TabletOral	Novadoz Pharmaceuticals LLC	72205-057
Bumetanide	Bumetanide 2 mg/1	TabletOral	Novadoz Pharmaceuticals LLC	72205-058